Webinar - CAR-T Cell Therapy for Generalized Myasthenia Gravis: Introduction to anito-cel

Join us to learn about anito-cel, a novel BCMA-targeted DNA CAR T-cell therapy that is being developed by Arcellx for generalized myasthenia gravis (gMG). Dr. Chris Heery, Chief Medical Officer at Arcellx, will explain how CAR T-cell therapy works and introduce the clinical trial of anito-cel in gMG. This webinar is sponsored by Arcellx.